Last updated: August 1, 2026
Rasagiline is an oral monoamine oxidase-B inhibitor approved for Parkinson's disease as monotherapy in early disease and as adjunctive therapy to levodopa in more advanced disease. Its clinical value is established for symptomatic control, but disease-modifying claims were not confirmed in the ADAGIO trial. The U.S. market is generic, with limited pricing power and low barriers to substitution. Commercial opportunity is concentrated in cost-sensitive markets, fixed-dose combinations, specialty distribution, and development programs that use rasagiline as a comparator or combination component.
What is rasagiline approved to treat?
Rasagiline, marketed as Azilect by Teva Pharmaceuticals and historically developed by Teva and Lundbeck, is approved for Parkinson's disease.
| Attribute |
Details |
| Active ingredient |
Rasagiline mesylate |
| Pharmacologic class |
Selective monoamine oxidase-B inhibitor |
| U.S. brand |
Azilect |
| U.S. approval |
May 16, 2006 |
| Initial indication |
Monotherapy for Parkinson's disease |
| Expanded indication |
Adjunct to levodopa in patients with motor fluctuations |
| Dosage strengths |
0.5 mg and 1 mg tablets |
| Standard adjunctive dose |
1 mg once daily |
| FDA pathway |
New drug application |
| Primary therapeutic competitors |
Selegiline, safinamide, dopamine agonists, levodopa formulations |
| Current U.S. market structure |
Generic-dominated |
The FDA approved rasagiline as monotherapy based on trials in patients with early Parkinson's disease and later approved adjunctive use with levodopa for patients with motor fluctuations. The product is administered once daily and does not require titration in the approved regimen [1].
Rasagiline is metabolized primarily through CYP1A2. The prescribing information restricts use with meperidine, tramadol, methadone, propoxyphene, dextromethorphan and other monoamine oxidase inhibitors because of potential serious central nervous system and cardiovascular reactions. Ciprofloxacin and other CYP1A2 inhibitors can increase rasagiline exposure [1].
What clinical trials established rasagiline's efficacy?
Rasagiline's pivotal evidence supports symptomatic improvement in motor function and reduction of off-time, rather than confirmed neuroprotection.
TEMPO and PRESTO trials
The TEMPO trial evaluated rasagiline in early Parkinson's disease. Patients receiving 1 mg or 2 mg daily had better Unified Parkinson's Disease Rating Scale outcomes than placebo over the treatment period [2].
The PRESTO trial studied patients with Parkinson's disease who had motor fluctuations while receiving levodopa. Rasagiline reduced daily off-time, with the 1 mg dose producing a clinically relevant improvement compared with placebo [3].
LARGO trial
The LARGO trial compared rasagiline with placebo and entacapone as adjunctive therapy to levodopa. Rasagiline 1 mg reduced daily off-time and improved motor symptoms. The study supported rasagiline as a levodopa adjunct but did not establish superiority over entacapone across all clinical measures [4].
ADAGIO disease-modification trial
The ADAGIO trial tested whether early initiation of rasagiline could slow Parkinson's disease progression. The trial used a delayed-start design with 1 mg and 2 mg doses.
The 1 mg group met some prespecified outcomes, but the 2 mg group did not meet the primary endpoint. The overall dataset did not provide a clear regulatory basis for a disease-modifying indication. Rasagiline remains approved for symptomatic treatment, not for slowing underlying neurodegeneration [5].
Are new rasagiline clinical trials still active?
Rasagiline has limited standalone late-stage development activity because its composition and core symptomatic indications are mature. Current research relevance is concentrated in combination therapy, earlier disease, biomarker-driven Parkinson's studies and comparative treatment strategies.
Clinical development status by research area
| Research area |
Status and commercial relevance |
| Monotherapy in early Parkinson's disease |
Established indication; limited differentiation |
| Adjunct to levodopa |
Established indication; remains the principal use case |
| Disease modification |
Unconfirmed after ADAGIO |
| Cognitive impairment in Parkinson's disease |
No established rasagiline indication |
| Dyskinesia reduction |
May improve motor fluctuation burden, but not a stand-alone dyskinesia product |
| Combination with other antiparkinsonian drugs |
Clinically relevant but generally commercially difficult because generic rasagiline is available |
| Neuroprotection and biomarkers |
Research interest remains, with no approved claim |
| New delivery systems |
Potentially differentiating, but no major FDA-approved reformulation has displaced tablets |
ClinicalTrials.gov should be used for a live trial-by-trial status review because Parkinson's disease studies can change status after registry updates. Rasagiline's commercially material clinical position remains its approved use with levodopa rather than a new indication [6].
What patents protect rasagiline and Azilect?
The principal rasagiline composition and formulation patents have expired or reached the end of their effective exclusivity periods in the United States. The original U.S. compound patent did not provide current generic protection.
| Patent or protection category |
Subject matter |
Commercial significance |
| U.S. Patent No. 5,532,415 |
Rasagiline compound and related chemical subject matter |
Expired; no current U.S. composition exclusivity |
| U.S. Patent No. 6,316,023 |
Pharmaceutical compositions and use-related subject matter |
Expired; historical barrier to generic entry |
| Orange Book-listed patents |
Product-specific patents for Azilect |
Historical basis for patent certification and litigation analysis |
| Pediatric exclusivity |
Regulatory extension, if granted |
Does not create a new composition patent |
| Data exclusivity |
New drug approval protection |
Expired for the original 2006 approval |
Patent term depends on filing date, patent-term adjustment, terminal disclaimers and applicable regulatory extensions. The FDA Orange Book and USPTO records provide the controlling source for current listing and expiration analysis [7,8].
Rasagiline's core intellectual-property estate is weak for a U.S. product seeking premium pricing. Potentially defensible areas include crystalline forms, impurities, manufacturing processes, combination products, modified-release systems and specific therapeutic methods. Those rights require separate claim-level review and do not automatically block an ordinary immediate-release generic tablet.
When does rasagiline lose exclusivity?
Rasagiline lost practical U.S. small-molecule exclusivity before the current period. FDA-approved generic rasagiline products entered the U.S. market in the late 2010s, and the commercial market is now driven mainly by generic pricing, formulary placement and supply reliability.
The relevant exclusivity sequence was:
| Milestone |
Approximate timing |
| Azilect U.S. approval |
2006 |
| Core compound patent expiration |
2012 |
| Historical formulation and use-patent period |
Through the late 2010s, depending on patent and adjustment |
| Generic U.S. entry |
2017 onward |
| Current status |
Generic competition; no meaningful brand monopoly |
A generic applicant generally must address listed patents through a Paragraph III certification, Paragraph IV certification or a statement that no relevant patent is listed. A Paragraph IV filing alleges that a listed patent is invalid, unenforceable or not infringed [9].
What is the FDA and Orange Book status of rasagiline?
Azilect is an FDA-approved prescription drug, while multiple generic rasagiline tablets have been approved through abbreviated new drug applications.
FDA regulatory position
The regulatory profile is mature:
- The active ingredient is rasagiline mesylate.
- The reference listed drug is Azilect.
- Approved strengths include 0.5 mg and 1 mg.
- The primary dosage form is an immediate-release oral tablet.
- Generic products must demonstrate pharmaceutical equivalence and bioequivalence to the reference product.
- No biosimilar pathway applies because rasagiline is a chemically synthesized small molecule, not a biologic.
FDA's Orange Book identifies approved products, therapeutic equivalence information and listed patent data. Patent listings can change, so the current FDA database should control any transaction, launch or litigation decision [7].
Which companies are challenging or competing with Azilect?
The competitive landscape has two tiers: generic rasagiline suppliers and branded or specialty Parkinson's disease products.
Generic rasagiline companies
U.S. generic competition has included major and specialty manufacturers such as Teva, Mylan/Viatris, Apotex, Zydus and other ANDA holders, subject to product availability and market withdrawals. The number of active suppliers can differ from the number of approved ANDAs because manufacturers may discontinue products or maintain limited distribution.
Branded therapeutic competitors
| Product |
Company or originator |
Mechanism |
Competitive position |
| Azilect |
Teva/Lundbeck heritage |
MAO-B inhibitor |
Original rasagiline brand; largely displaced by generics |
| Eldepryl/Zelapar |
Selegiline originators and generics |
MAO-B inhibitor |
Older class competitor; different dosage forms and interaction profile |
| Xadago |
Zambon |
MAO-B inhibitor with additional pharmacology |
Branded alternative for adjunctive treatment |
| Entacapone products |
Multiple manufacturers |
COMT inhibitor |
Competes for levodopa adjunct use |
| Rytary |
Amneal |
Extended-release carbidopa/levodopa |
Competes through levodopa delivery rather than MAO-B inhibition |
| Gocovri |
Adamas/previously Supernus |
Amantadine extended release |
Targets dyskinesia and off episodes |
| Nourianz |
Kyowa Kirin |
Adenosine A2A antagonist |
Adjunctive therapy for off episodes |
Rasagiline's main disadvantage against branded alternatives is limited differentiation. Its advantages are once-daily dosing, established evidence, generic availability and generally lower cost.
What patent litigation affected rasagiline generic entry?
Rasagiline's generic-entry disputes centered on the validity, enforceability and scope of Azilect's listed patents. The relevant litigation period was primarily before broad generic commercialization.
Generic applicants using Paragraph IV certifications could trigger the 30-month stay under the Hatch-Waxman framework if the brand holder filed an infringement action within the statutory period. Generic entry could then occur upon patent expiration, settlement terms, court judgment or FDA approval after resolution of the stay.
The commercial consequence was more important than the litigation itself: once the core patent barriers expired, rasagiline became a conventional generic product. No current U.S. litigation appears to restore broad exclusivity for the original molecule or immediate-release tablet.
Settlement agreements and launch timing
Historical settlement terms involving generic applicants can affect the earliest launch date, authorized-generic strategy and damages exposure. Such agreements require review through court dockets, FTC submissions and FDA approval records. A generic settlement does not necessarily imply that all patents were valid; it can reflect the cost and timing of litigation, supply arrangements or an agreed entry date.
How strong is the rasagiline patent estate?
The patent estate is weak for the original immediate-release product and potentially stronger for differentiated delivery or combination technology.
| IP segment |
Strength |
Reason |
| Core rasagiline molecule |
Low |
Foundational patents expired |
| Immediate-release 0.5 mg and 1 mg tablets |
Low |
Generic products are approved |
| Approved monotherapy method |
Low |
Long-established use and generic substitution |
| Adjunctive levodopa method |
Low to moderate |
Clinical use is established, but broad claims face prior-art pressure |
| New formulation |
Moderate if claims are technically narrow |
Protection depends on formulation novelty and enablement |
| Manufacturing process |
Moderate in selected jurisdictions |
Process claims can matter if difficult to design around |
| Combination therapy |
Moderate |
Value depends on clinical benefit and claim scope |
| Disease-modifying claim |
Low regulatory value |
ADAGIO did not establish the required clinical basis |
A licensing or acquisition decision should focus on claim breadth, remaining patent term, freedom to operate, process reproducibility and evidence of clinical differentiation. A patent on a specific formulation does not block an ordinary generic rasagiline tablet unless the generic product practices the asserted claims.
What formulations are protected by rasagiline patents?
The commercial reference product is an immediate-release tablet. Potential formulation claims can cover:
- Specific salt forms.
- Particle size or polymorph characteristics.
- Excipients and dissolution profiles.
- Oral disintegrating tablets.
- Modified-release tablets.
- Combination tablets with levodopa, carbidopa or other Parkinson's medicines.
- Stabilized formulations with defined impurity limits.
- Manufacturing processes that control stereochemical purity or degradation products.
The technical opportunity is limited by the drug's low daily dose and established oral administration. A new formulation needs a measurable clinical or commercial advantage, such as improved adherence, reduced interaction risk, easier administration in dysphagic patients or combination-product convenience.
What generic entry risks exist for rasagiline?
Generic entry risk is high in the United States and other mature markets. The principal risks are commercial rather than legal.
U.S. launch scenarios
| Scenario |
Probability profile |
Market effect |
| Several generic suppliers remain active |
Base case |
Continued price erosion and low brand share |
| Supplier consolidation or shortage |
Intermittent risk |
Temporary price increases and pharmacy substitution shifts |
| New branded formulation launches |
Low to moderate |
Possible niche premium if clinically differentiated |
| Generic combination product launches |
Moderate technical interest |
Could improve convenience but faces reimbursement pressure |
| New disease-modifying evidence emerges |
Low based on current evidence |
Would require a new indication and separate clinical program |
A generic manufacturer may face limited profitability because rasagiline has a small market, low tablet volume and multiple approved competitors. Supply interruptions can create temporary share gains, but they are not a durable basis for a branded investment thesis.
How large is the rasagiline market?
Public market reports often combine rasagiline with the broader Parkinson's disease drug market, making rasagiline-only revenue figures difficult to validate. The product's U.S. revenue has declined sharply from the branded Azilect period because of generic substitution.
Market drivers
The demand base is supported by:
- Growth in the diagnosed Parkinson's disease population.
- Longer treatment duration.
- Use as an adjunct to levodopa.
- Low-cost access in generic markets.
- Continued use in countries where rasagiline remains routinely prescribed.
The market is constrained by:
- Generic price erosion.
- Competition from safinamide and selegiline.
- Broad use of levodopa optimization strategies.
- Limited evidence for disease modification.
- Absence of a major new formulation with a clear clinical advantage.
2025-2030 market projection
The following projection applies to global rasagiline product revenue, including brand and generic sales, rather than the entire Parkinson's disease market. It is a scenario model using a low-single-digit volume growth assumption from Parkinson's disease prevalence and a higher negative net-price trend from generic competition.
| Year |
Low case |
Base case |
High case |
| 2025 |
$180 million |
$240 million |
$320 million |
| 2026 |
$172 million |
$233 million |
$314 million |
| 2027 |
$164 million |
$226 million |
$308 million |
| 2028 |
$157 million |
$219 million |
$302 million |
| 2029 |
$150 million |
$213 million |
$296 million |
| 2030 |
$144 million |
$207 million |
$290 million |
| 2025-2030 CAGR |
-4.4% |
-3.0% |
-2.0% |
The base case assumes stable prescription volume, continued generic substitution and no approved premium formulation. The high case assumes stronger diagnosis and treatment persistence in emerging markets, while the low case assumes further price compression and substitution by other adjunctive therapies.
The addressable opportunity is larger in units than in revenue. Rasagiline can maintain or increase tablet volume while total sales decline because generic net prices fall faster than demand grows.
How does rasagiline compare with safinamide?
Rasagiline and safinamide both support adjunctive treatment in Parkinson's disease, but their commercial profiles differ.
| Factor |
Rasagiline |
Safinamide |
| Mechanism |
Selective MAO-B inhibition |
MAO-B inhibition with additional sodium-channel and glutamate-related effects |
| Dosing |
Once daily |
Once daily |
| U.S. status |
Generic and brand history |
Branded product |
| Price position |
Low |
Premium |
| Evidence base |
Established monotherapy and adjunct use |
Primarily adjunctive use with levodopa |
| Patent value |
Core estate expired |
Newer product estate, subject to patent review |
| Commercial risk |
Price erosion |
Reimbursement and patent exposure |
| Main differentiation |
Familiarity, low cost, long clinical history |
Branded differentiation and later-generation positioning |
Rasagiline is more attractive for volume-based generic strategies. Safinamide is more attractive for a branded strategy only if clinical outcomes, payer access and patent duration support the premium.
What licensing and partnering opportunities exist for rasagiline?
The most credible licensing opportunities involve delivery, combination therapy and geographic commercialization rather than the original molecule.
Potential transaction targets include:
- Regional rights in markets where rasagiline remains underpenetrated.
- Fixed-dose combinations with carbidopa/levodopa.
- Orally disintegrating or swallow-friendly formulations.
- Manufacturing technology that lowers impurity levels or improves yield.
- Specialty generic distribution through neurology-focused channels.
- Combination development with therapies targeting dyskinesia or motor fluctuations.
A license for ordinary rasagiline tablets is unlikely to command a substantial premium unless it includes protected territory, a reliable supply advantage or a differentiated formulation. Product rights should be valued against generic net pricing, regulatory filing costs, manufacturing redundancy and expected formulary substitution.
What geographic markets are most relevant?
Rasagiline has broad international regulatory exposure, but market value varies substantially by patent status, reimbursement and generic penetration.
United States
The U.S. market is mature and generic. The primary opportunities are supply reliability, contract manufacturing, specialty pharmacy distribution and niche dosage forms.
Europe
European markets are fragmented by national reimbursement systems and tendering. Generic substitution is extensive, while neurologist prescribing patterns vary by country. Local marketing authorization, pharmacovigilance and tender access are more important than broad patent exclusivity.
China and other Asian markets
Diagnosis rates, specialist access and treatment penetration can support volume growth. Price controls and local generic competition limit revenue per patient. Local manufacturing and registration strategy can materially affect market share.
Latin America and other emerging markets
The opportunity is volume-led. Distribution, registration, import requirements and affordability determine commercial performance. A low-cost, stable-supply product can compete effectively without a differentiated patent estate.
What manufacturing and intellectual-property barriers remain?
Rasagiline synthesis requires control of stereochemistry, impurity profile and batch consistency. The molecule's commercial manufacturing barriers are manageable for experienced generic manufacturers, but regulatory execution remains important.
Key technical risks include:
- Control of the R-enantiomer and unwanted stereoisomers.
- Residual solvent and process impurity limits.
- Stability of the mesylate salt.
- Tablet dissolution and content uniformity.
- Consistent low-dose manufacturing.
- Demonstration of bioequivalence.
- Supply continuity for active pharmaceutical ingredient.
Manufacturing-process patents can create jurisdiction-specific barriers even when composition patents have expired. A design-around process may reduce legal exposure but increase validation cost or impurity risk.
Key Takeaways
- Rasagiline is an established symptomatic treatment for Parkinson's disease, used alone in early disease and with levodopa in motor fluctuations.
- TEMPO, PRESTO and LARGO established efficacy for motor symptoms and off-time reduction.
- ADAGIO did not establish a disease-modifying indication.
- U.S. exclusivity has ended, and the market is generic-dominated.
- The core rasagiline patent estate has limited current blocking power.
- Paragraph IV litigation was primarily relevant before generic commercialization.
- No biosimilar pathway applies; rasagiline is a small-molecule generic product.
- The base-case global rasagiline market is projected to decline from about $240 million in 2025 to $207 million in 2030 as price erosion exceeds volume growth.
- Commercial upside is concentrated in formulations, combinations, emerging markets and reliable generic supply.
- A branded investment requires a clinically meaningful delivery or combination advantage, not merely a new trade name.
FAQs about rasagiline patents, trials and market outlook
Is rasagiline still commercially relevant after generic entry?
Yes. It remains clinically relevant as a low-cost once-daily adjunct to levodopa, although generic competition has sharply reduced revenue per prescription.
Does rasagiline slow Parkinson's disease progression?
No disease-modifying benefit has been established for regulatory purposes. The ADAGIO trial produced mixed results and did not support a disease-modifying indication.
Can a company obtain new patents on rasagiline?
Potentially. New patents may cover formulations, combinations, manufacturing processes or narrowly defined methods. A new patent would not automatically block existing immediate-release generics.
Is rasagiline a substitute for levodopa?
No. Rasagiline is commonly used as monotherapy in selected early patients or as an adjunct to levodopa. It does not replace levodopa for patients who require stronger symptomatic control.
What is the most attractive rasagiline investment strategy?
A differentiated product with enforceable formulation or combination claims is more attractive than an ordinary tablet. Generic strategies depend on manufacturing cost, supply reliability, tender access and geographic scale.
References
-
U.S. Food and Drug Administration. (2020). Azilect (rasagiline mesylate) prescribing information. FDA.
-
Parkinson Study Group. (2002). A controlled trial of rasagiline in early Parkinson disease: The TEMPO study. Archives of Neurology, 59(12), 1937-1943.
-
Parkinson Study Group. (2005). A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Archives of Neurology, 62(2), 241-248.
-
Rascol, O., Barone, P., Hauser, R. A., Mizuno, Y., Salin, L., Sohr, M., Debieuvre, C., & LARGO Study Group. (2005). A double-blind, placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The LARGO study. Archives of Neurology, 62(2), 241-248.
-
Olanow, C. W., Rascol, O., Hauser, R., Feigin, A., Jankovic, J., Lang, A., Langston, W., Melamed, E., Poewe, W., Stocchi, F., Tolosa, E., & ADAGIO Study Investigators. (2009). A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New England Journal of Medicine, 361(13), 1268-1278.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov: Rasagiline studies. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
United States Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 5,532,415 and 6,316,023. USPTO.
-
U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity when multiple ANDA applicants are eligible for 180-day exclusivity. FDA.